Pfizer Announces FDA Approval of ELELYSO™ for Type 1 Gaucher Disease and Personal Support Program For Patients

May 16, 2012

On May 1, 2012, Pfizer announced the FDA approval of ELELYSO(taliglucerase alfa), an enzyme replacement therapy (ERT) for adults diagnosed with a rare genetic disorder called type 1 Gaucher disease.  ELELYSO, the first FDA-approved plant cell-based ERT for Gaucher disease, is also recognized for being acquired through a genetically engineered manufacturing system.

This news comes with great optimism within the Gaucher community as there are only two other ERT’s available for Gaucher disease in the U.S., which have experienced supply problems and have impacted Gaucher patients.  With the availability of ELELYSO™, Pfizer plans to launch a “Supply Continuity Program” to ensure continuous supplies of ELELYSO™ within various stages of production for type 1 Gaucher patients.

Pfizer Launches Gaucher Personal Support (GPS) program for Patients

Mariah Kelly, a registered nurse (RN) and Pfizer’s Patient Affairs Liaison, will be working directly with the Gaucher and rare disease communities as a resource for non-medical issues critical to Gaucher patients.  Her dedication and passion to help address the needs and challenges the Gaucher community often face are reflective in her work with patient advocacy groups and within Pfizer. Mariah can be reached at here.

With the approval of  ELELYSO™, support for Gaucher patients is a top priority for Pfizer.  With the Gaucher Personal Support (GPS) program, a dedicated staff of GPS health care specialists will be available 24 hours a day, 7 days a week offering free patient information kits for ELELYSO™, reimbursement assistance, and ongoing pharmacy support.  Patients can call 1-855-ELELYSO (1-855-353-5976) for more information.

Want to learn more?  The following is a key list of resources available to those looking for additional information.

May 1, 2012 – Pfizer, Inc. Press Release

ELELYSO™ Frequently Asked Questions

Gaucher Personal Support™ (GPS)

Stay Connected

Sign up for updates straight to your inbox.